P. Hofman, S. Heeke, C. Alix-panabières, and K. Pantel, Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients?, Ann. Oncol, 2019.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. Esteban, E. Felip et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.378, pp.2078-2092, 2018.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015.

D. R. Camidge, R. C. Doebele, and K. M. Kerr, Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC, Nat. Rev. Clin. Oncol, vol.16, pp.341-355, 2019.

J. Mclaughlin, G. Han, K. A. Schalper, D. Carvajal-hausdorf, V. Pelekanou et al., Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol, vol.2, pp.46-54, 2016.

C. Grigg and N. A. Rizvi, PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction?, J Immunother Cancer. J. Immunother. Cancer, vol.4, 2016.

M. Kowanetz, W. Zou, S. N. Gettinger, H. Koeppen, M. Kockx et al., Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1), Proc. Natl. Acad. Sci, vol.115, pp.10119-10126, 2018.

Y. Tseng, H. Ho, C. Lai, Y. Luo, Y. Tseng et al., PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion, J. Thorac. Oncol, vol.13, pp.447-453, 2018.

G. Mazzaschi, D. Madeddu, A. Falco, G. Bocchialini, M. Goldoni et al., Low PD-1 Expression in Cytotoxic CD8 + Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value, Clin. Cancer. Res, vol.24, pp.407-419, 2018.

S. Kitano, T. Nakayama, and M. Yamashita, Biomarkers for Immune Checkpoint Inhibitors in Melanoma, Front Oncol, 2018.

A. M. Goodman, S. Kato, L. Bazhenova, S. P. Patel, G. M. Frampton et al., Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol. Cancer Ther, vol.16, pp.2598-2608, 2017.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, vol.348, pp.124-128, 2015.

M. Lauss, M. Donia, K. Harbst, R. Andersen, S. Mitra et al., Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma, Nat. Commun, vol.8, pp.1-10, 2017.

R. M. Samstein, C. H. Lee, A. N. Shoushtari, M. D. Hellmann, R. Shen et al., Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet, vol.51, pp.202-206, 2019.

L. Danilova, H. Wang, J. Sunshine, G. J. Kaunitz, T. R. Cottrell et al., Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors, Proc. Natl. Acad. Sci, vol.113, pp.7769-7777, 2016.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N. Engl. J. Med, vol.378, pp.2093-2104, 2018.

N. Ready, M. D. Hellmann, M. M. Awad, G. A. Otterson, M. Gutierrez et al., First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers, J. Clin. Oncol, vol.37, pp.992-1000, 2019.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017.

M. D. Hellmann, T. Nathanson, H. Rizvi, B. C. Creelan, F. Sanchez-vega et al., Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018.

Z. R. Chalmers, C. F. Connelly, D. Fabrizio, L. Gay, S. M. Ali et al., Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, pp.1-14, 2017.

R. Chaudhary, L. Quagliata, J. P. Martin, I. Alborelli, D. Cyanam et al., A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay, Transl. Lung Cancer Res, vol.7, pp.616-630, 2018.

H. Rizvi, F. Sanchez-vega, K. La, W. Chatila, P. Jonsson et al., Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J. Clin. Oncol, vol.36, pp.633-641, 2018.

L. F. Campesato, R. Barroso-sousa, L. Jimenez, and A. A. Camargo, Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice, Oncotarget, vol.6, pp.34221-34227, 2015.

J. Leichsenring, E. Rempel, A. Lier, R. Penzel, S. Fröhling et al., Implementing tumor mutational burden (TMB) analysis in routine diagnostics-A primer for molecular pathologists and clinicians, Transl. Lung Cancer Res, vol.7, pp.703-715, 2018.

J. Budczies, M. Allgäuer, K. Litchfield, E. Rempel, P. Christopoulos et al., Optimizing panel-based tumor mutational burden (TMB) measurement, Ann. Oncol, 2019.

S. Heeke and P. Hofman, Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: Getting ready for prime-time or not? Transl, Lung Cancer Res, vol.7, pp.631-638, 2018.

T. A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. A. Quezada et al., Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic, Ann. Oncol, vol.30, pp.44-56, 2019.

K. Hatakeyama, T. Nagashima, K. Urakami, K. Ohshima, M. Serizawa et al., Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing, Biomed. Res, vol.39, pp.159-167, 2018.

W. Tom, R. Chaudhary, V. Mittal, D. Cyanam, I. Casuga et al., Improvement of tumor mutation burden measurement by removal of deaminated bases in FFPE DNA, Proceedings of the AACR Annual Meeting, 2019.

, Abstract 1701, p.1701

M. Serizawa, T. Yokota, A. Hosokawa, K. Kusafuka, T. Sugiyama et al., The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues, Cancer Genet, vol.208, pp.415-427, 2015.

E. M. Gorden, K. Sturk-andreaggi, and C. Marshall, Repair of DNA damage caused by cytosine deamination in mitochondrial DNA of forensic case samples, Forensic Sci. Int. Genet, vol.34, pp.257-264, 2018.

E. Samorodnitsky, B. M. Jewell, R. Hagopian, J. Miya, M. R. Wing et al., Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing, Hum. Mutat, vol.36, pp.903-914, 2015.

D. Kazdal, V. Endris, M. Allgäuer, M. Kriegsmann, J. Leichsenring et al., Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: Separating biology from technical artifacts, J. Thorac. Oncol, 2019.

V. Endris, I. Buchhalter, M. Allgäuer, E. Rempel, A. Lier et al., Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: In silico and real-life analysis of three larger gene panels, Int. J. Cancer, vol.144, pp.2303-2312, 2019.

H. Wu, Z. Wang, Q. Zhao, F. Wang, and R. Xu, Designing gene panels for tumor mutational burden estimation: The need to shift from 'correlation' to 'accuracy, J. Immunother. Cancer, vol.7, p.206, 2019.

A. Forschner, F. Battke, D. Hadaschik, M. Schulze, S. Weißgraeber et al., Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma -results of a prospective biomarker study, J. Immunother. Cancer, vol.7, p.180, 2019.

W. Hugo, J. M. Zaretsky, L. Sun, C. Song, B. H. Moreno et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, pp.35-44, 2016.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009.

M. Ilié, E. Szafer-glusman, V. Hofman, E. Chamorey, S. Lalvée et al., Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer, Ann. Oncol, vol.29, pp.193-199, 2018.

M. Ilie, A. T. Falk, C. Butori, E. Chamorey, C. Bonnetaud et al., PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1 + and CD8 + tumor-infiltrating T cells and outcome, Mod. Pathol, vol.29, pp.1552-1564, 2016.

F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion et al., Scikit-learn: Machine Learning in Python, J. Mach. Learn Res, vol.12, pp.2825-2830, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00650905